-
1.
公开(公告)号:US20240000842A1
公开(公告)日:2024-01-04
申请号:US18317616
申请日:2023-05-15
Inventor: Griffith Parks , Alicja Copik
IPC: A61K35/17 , A61K35/768 , C07K14/705 , C07K16/00 , C12N7/00
CPC classification number: A61K35/17 , A61K35/768 , C07K14/705 , C07K16/00 , C12N7/00 , C12N2760/18721 , C12N2760/18732 , C12N2760/18745
Abstract: Disclosed are engineered oncolytic viruses, related fusion proteins and polynucleotides encoding them, and methods for treating cancer using the engineered viruses.
-
公开(公告)号:US11684637B2
公开(公告)日:2023-06-27
申请号:US16616671
申请日:2018-05-25
Inventor: Griffith Parks , Alicja Copik
IPC: A61K35/76 , A61K35/768 , C07K14/705 , C12N7/00 , A61K35/17 , C07K16/00
CPC classification number: A61K35/17 , A61K35/768 , C07K14/705 , C07K16/00 , C12N7/00 , C12N2760/18721 , C12N2760/18732 , C12N2760/18745
Abstract: Disclosed are engineered oncolytic viruses, related fusion proteins and polynucleotides encoding them, and methods for treating cancer using the engineered viruses. In one aspect, disclosed herein are engineered oncolytic viruses, wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor.
-
公开(公告)号:US20210145876A1
公开(公告)日:2021-05-20
申请号:US16616671
申请日:2018-05-25
Inventor: Griffith Parks , Alicja Copik
IPC: A61K35/17 , C12N7/00 , C07K16/00 , C07K14/705 , A61K35/768
Abstract: Disclosed are engineered oncolytic viruses, related fusion proteins and polynucleotides encoding them, and methods for treating cancer using the engineered viruses. In one aspect, disclosed herein are engineered oncolytic viruses, wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor.
-
公开(公告)号:US20200237822A1
公开(公告)日:2020-07-30
申请号:US16752040
申请日:2020-01-24
Inventor: Alicja Copik , Griffith Parks , Jeremiah Oyer
IPC: A61K35/17 , C07K14/735 , C07K14/115 , C07K14/54 , A61P35/04
Abstract: Compositions and methods for stimulating NK cell expansion and cytotoxicity are described. Therapeutic compositions and methods using expanded and stimulated NK cells are described.
-
-
-